Bianchi Elisa, Pupillo Elisabetta, De Feudis Antonio, Enia Gabriele, Vitelli Eugenio, Beghi Ettore
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.
Amyotroph Lateral Scler Frontotemporal Degener. 2022 Aug;23(5-6):344-352. doi: 10.1080/21678421.2021.2004167. Epub 2021 Nov 24.
To assess survival of ALS patients in general and in selected demographic and clinical subgroups comparing two periods (1998-2000 vs. 2008-2010). Newly diagnosed adults resident of Lombardy, Northern Italy from a population-based registry were included. Data were collected on age at diagnosis, sex, site of onset, diagnostic delay, and El-Escorial diagnostic category. Patients were followed until death or last observation. Survival was evaluated using Kaplan-Meier curves and Cox's proportional hazards models. In 2008-2010 (267 patients), median survival was 2.4 years and 1-year, 2-year, 3-year and 5-year survival rates were 79%, 56%, 41% and 24%. Longer survival was associated with male sex, younger age, spinal onset, and longer diagnostic delay. Multivariable analysis confirmed higher death in 65-69yr (HR 2.8; 95% CI 1.4-5.6), 70-74yr (HR 3.2; 95% CI 1.6-6.3) and 75 + yr (HR 6.9; 95% CI 3.5-13.8) categories, compared to ≤49yr, in females (HR 1.4; 95% CI 1.02-1.8), compared to males, and in patients diagnosed after 6-12 months (HR 1.9; 95% CI 1.4-2.7), compared with longer diagnostic delay. In 1998-2000 (235 patients), median survival was 2.2 years. The 1-year, 2-year, 3-year and 5-year survival rates were 77%, 53%, 38% and 20%. When adjusting for demographic and clinical variables, the HR for death in 2008-2010 versus 1998-2000 was 0.80 (95% CI 0.66-0.98). A significant increase of survival in 2008-2010 was found only in patients aged 50-59yr and 70-74yr at diagnosis. Survival of ALS has increased over time in the last decades, especially in middle aged and elderly patients. The benefits of comprehensive care in selected age groups might explain our findings.
为评估肌萎缩侧索硬化症(ALS)患者总体以及特定人口统计学和临床亚组在两个时期(1998 - 2000年与2008 - 2010年)的生存率。纳入了来自意大利北部伦巴第地区基于人群登记处的新诊断成年居民。收集了诊断时的年龄、性别、发病部位、诊断延迟以及埃尔 - 埃斯科里亚尔诊断类别等数据。对患者进行随访直至死亡或最后一次观察。使用卡普兰 - 迈耶曲线和考克斯比例风险模型评估生存率。在2008 - 2010年(267例患者),中位生存期为2.4年,1年、2年、3年和5年生存率分别为79%、56%、41%和24%。较长的生存期与男性、较年轻的年龄、脊髓发病以及较长的诊断延迟相关。多变量分析证实,与年龄≤49岁的患者相比,65 - 69岁(风险比[HR] 2.8;95%置信区间[CI] 1.4 - 5.6)、70 - 74岁(HR 3.2;95% CI 1.6 - 6.3)和75岁及以上(HR 6.9;95% CI 3.5 - 13.8)年龄组的女性(HR 1.4;95% CI 1.02 - 1.8)与男性相比,以及诊断后6 - 12个月的患者(HR 1.9;95% CI 1.4 - 2.7)与诊断延迟较长的患者相比,死亡风险更高。在1998 - 2000年(235例患者),中位生存期为2.2年。1年、2年、3年和5年生存率分别为77%、53%、38%和20%。在调整人口统计学和临床变量后,2008 - 2010年与1998 - 2000年相比的死亡HR为0.80(95% CI 0.66 - 0.98)。仅在诊断时年龄为50 - 59岁和70 - 74岁的患者中发现2008 - 2010年生存率有显著提高。在过去几十年中,ALS患者的生存率随时间增加,尤其是在中年和老年患者中。特定年龄组综合护理的益处可能解释了我们的研究结果。